Moist-heat resistance, spore aging, and superdormancy in Clostridium difficile
Walter adds that these conversations matter because the GLP-1 landscape is evolving fast from clinical obesity treatment to more nuanced, personalized wellness strategies
IDF Diabetes Atlas, 11th Edition
Key players include Novo Nordisk, Eli Lilly and Company, Pfizer, Amgen, AstraZeneca, Boehringer Ingelheim, Sanofi, Regeneron, Viking Therapeutics, Inc., and Terns Pharmaceuticals - competing across injectable, oral, and next-gen incretin-based therapies
Conditional Weight-Loss Guarantee Health RX states that a qualifying new customer may receive a refund of the first four months of program membership fees when the customer loses less than 10% of starting weight after 16 consecutive weekly prescribed doses
Thyroid axis dysfunction in patients with Prader-Willi syndrome during the first 2 years of life